Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 1 symbols : INCY save search
Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
Published: 2022-12-05 (Crawled : 12:20) - biospace.com/
SNDX | $20.75 -2.49% -2.55% 1.7M
|
Health Technology
|
| O: -0.28%
H: 4.28%
C: 1.76%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.43%
H: 2.17%
C: 1.58%
pharmaceuticals disease phase 1
Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies
Published: 2022-08-24 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -4.66%
H: 0.0%
C: -1.69%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.43%
H: 1.39%
C: 0.76%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.16%
H: 0.56%
C: -0.19%
ibi363 australia antibody study phase 1
Innovent Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody)
Published: 2022-08-18 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -5.88%
H: 3.23%
C: 3.23%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.02%
H: 0.7%
C: -0.01%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -1.55%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.24%
H: 0.48%
C: -0.08%
ibi311 study phase 1
Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema
Published: 2022-08-08 (Crawled : 01:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.0%
H: 2.7%
C: 2.55%
ibi324 macular study diabetic phase 1
Innovent Releases Results of High-dose Cohorts in Phase 1 Clinical Study of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity at ENDO 2022
Published: 2022-06-13 (Crawled : 01:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -3.12%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -3.69%
H: 0.0%
C: 0.0%
ibi362 obesity chinese results phase 1
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022
Published: 2022-04-11 (Crawled : 01:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.82%
H: 0.59%
C: -1.88%
ibi322 results antibody phase 1
Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-03-29 (Crawled : 01:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.13%
H: 0.38%
C: -1.25%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.05%
H: 1.43%
C: 1.01%
ibi389 trial antibody phase 1
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-02-23 (Crawled : 01:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.59%
H: 0.89%
C: -0.93%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.87%
H: 0.84%
C: -1.12%
cd73 trial phase 1 antibody phase 1b
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-02-24 (Crawled : 01:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -1.25%
H: 1.21%
C: 1.04%
cd73 trial phase 1 antibody phase 1b
Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Dual Glucagon-like Peptide-1 and Glucagon Receptor Agonist in Chinese Patients with Type 2 Diabetes at the International Diabetes Federation Congress 2021
Published: 2021-12-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.84%
H: 0.49%
C: 0.36%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -1.43%
H: 3.35%
C: 2.19%
chinese diabetes phase 1 results
Significant Weight Loss and Multiple Metabolic Benefits: Phase 1b Study Results of IBI362 in Chinese Participants with Overweight or Obesity Published in EClinicalMedicine by the Lancet
Published: 2021-08-18 (Crawled : 00:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.26%
H: 1.01%
C: -1.28%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.11%
H: 0.15%
C: -1.38%
weight loss chinese obesity phase 1 results metabolic phase 1b lancet phase 2b
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
Published: 2021-07-26 (Crawled : 00:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 1.53%
H: 1.12%
C: 0.26%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.49%
H: 0.51%
C: -1.85%
phase 1 antibody phase 2
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors
Published: 2021-07-16 (Crawled : 01:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.3%
H: 0.44%
C: -2.37%
phase 1 antibody phase 2
Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.18%
H: 2.77%
C: 1.95%
chinese solid tumors phase 1 results phase 3 phase 2
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.